Alirocumab not checked

Regeneron · REGN727 · SAR236553

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
4 active
10 in total · 4 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
Tested for
Hypercholesterolemia
Main trialPhase 2
“This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug once a week * How much study drug is in the blood at different times”In the company’s words, NCT07477704 on ClinicalTrials.gov
Other names
Praluent · REGN727 · SAR236553

Other drugs for Hypercholesterolemia

All 21 drugs for Hypercholesterolemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 29 Dec 2026 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
Phase 4Completed 5 Mar 2020 Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Phase 4Terminated 8 Apr 2020 Long Term Safety Study of PRALUENT
Phase 3Completed 12 Apr 2019 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Phase 3Completed 27 Sep 2019 Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Phase 3Completed 14 Jan 2021 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Phase 4Ended not given ACAV: EFFICACY AND SAFETY OF ALIROCUMAB TO PREVENT EARLY CARDIAC ALLOGRAFT VASCULOPATHY IN RECENT HEART TRANSPLANT RECIPIENTS
Phase 3Authorised not given Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial
Phase 4Authorised not given The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis
Phase 4Authorised not given Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Alirocumab

Following is part of Solo: you see every change to Alirocumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in